UC San Diego Health has enrolled its first patient to evaluate a hand-held technology to fragment kidney stones. The clinical trial will assess the safety and effectiveness of breaking up kidney stones using acoustic energy.
In a media roundtable at 11 a.m. U.S. Central on Tuesday, October 15, leading neuroscientists will summarize key science being presented at the American Neurological Association’s 2019 Annual Meeting (ANA2019). Reporters may attend in person or dial in.
Psilocybin, a psychedelic drug believed to help rewire the brain, is now being studied to relieve treatment-resistant depression at The University of Texas Health Science Center at Houston (UTHealth) as part of a global Phase II clinical trial.
Georgetown University Medical Center, a Lewy Body Dementia (LBD) Association Research Center of Excellence, is now offering three clinical trials to study new treatments for LBD, a disease often confused with Parkinson’s and Alzheimer’s disease.
Researchers in WMG at the University of Warwick have developed a new method that could solve the problem of how to automate support of managing the complexities of care when applying multiple clinical practice guidelines, to patients with more than one medical issue.
A new nationwide clinical trial hopes to discover if patients that experience cardiac arrest survive more often and have a better recovery based on how long they have their body temperature cooled.
A new test to determine whether antibiotics will be effective against certain bacterial infections is helping physicians make faster and better prescription treatment choices.
Point-of-care testing is transforming healthcare: this type of testing helps patients get diagnosed and treated faster, and also makes it easier for patients in remote areas to have access to medical testing. Join AACC and leading experts in laboratory medicine for a discussion about what lies ahead for point-of-care testing and what needs to happen so that all patients can benefit from quality testing of this kind.
MedStar Heart & Vascular Institute has enrolled its first patient to a clinical trial to determine whether cardiac stem cells reduce inflammation enough to improve heart function in patients with heart failure severe enough to require a left ventricular assist device, or LVAD.
Kayla and Lance Edwards are excited to publicly announce the birth of their daughter Indy Pearl Edwards through a landmark uterus transplant clinical trial at Baylor University Medical Center at Dallas, a part of Baylor Scott & White Health.
A panel of international scientists led by researchers at Dalhousie and McMaster universities systematically reviewed the evidence and have recommended that most adults should continue to eat their current levels of red and processed meat.
Researchers investigated the safety and efficacy of deep brain stimulation in the treatment of refractory severe tinnitus in a small group of patients. They found the procedure to be safe and the results to be encouraging.
The Division of Movement Disorders at Hackensack University Medical Center has been selected to participate in the RESTORE-1 Phase 2 Clinical Study of VY-AADC, an investigational gene therapy for Parkinson’s disease.
A randomized clinical trial led at Children's Hospital Los Angeles by Leo Mascarenhas, MD, MS, showed first positive results in rhabdomyosarcoma since 1974.
A new $3 million grant to support a clinical trial evaluating a combination therapy to prevent triple-negative breast cancer from recurring, which will be led in the clinic by Angela DeMichele, MD, MSCE, the Alan and Jill Miller Professor in Breast Cancer Excellence in the Abramson Cancer Center (ACC) at the University of Pennsylvania and co-director of the ACC’s 2-PREVENT Translational Center of Excellence. The grant was awarded by Stand Up 2 Cancer (SU2C) in partnership with Genentech, and will be administered by the organization’s scientific partner, the American Association for Cancer Research (AACR).
Children’s of Alabama’s Cancer Predisposition Clinic physicians develop personalized screening for children who have inherited cancer predisposition syndromes with hopes that early detection will lead to improved outcomes.
Ventrix, a University of California San Diego spin-off company, has successfully conducted a first-in-human, FDA-approved Phase 1 clinical trial of an injectable hydrogel that aims to repair damage and restore cardiac function in heart failure patients who previously suffered a heart attack.
Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis
Ablacon, Inc. (www.ablacon.com), an Ajax Health-funded company, announced today the release of an updated version of its Ablamap technology under the company's existing CE Mark.
The University of Kansas Cancer Center and Midwest Cancer Alliance have been awarded a grant to expand the reach of cancer clinical trials to Kansas’ rural communities.
Irvine, Calif., Sept. 5, 2019 – The Institute for Clinical & Translational Science at the University of California, Irvine has been awarded $24 million over five years from the National Institutes of Health as part of its Clinical & Translational Science Awards program.
Investigators at Case Western Reserve University School of Medicine, the Case Comprehensive Cancer Center and University Hospitals Cleveland Medical Center developed the test for early detection of Barrett’s esophagus that offers promise for preventing deaths from esophageal adenocarcinoma.
A drug developed by researchers at the Renaissance School of Medicine at Stony Brook University that targets enzymes involved in the development of pancreatic cancer cells is showing promise for improved treatment of metastatic pancreatic cancer.
Danbury Hospital and Norwalk Hospital received approval to join NRG Oncology as primary clinical research sites. This means that patients at Danbury Hospital and Norwalk Hospital now have expanded access to the latest clinical trials for breast cancer, radiation oncology, and gynecologic cancer.
Researchers have decoded a chain of molecules that are critical for the growth and survival of pancreatic ductal adenocarcinoma—the most common and also the most lethal form of pancreatic cancer.
Ground-breaking immune therapy promises to deliver vital evidence in the fight against cancer as researchers from the Centre for Cancer Biology open a new clinical trial using genetically engineered immune cells to treat solid cancers.
Mount Sinai researchers have found a new type of therapy to be effective for patients with a particular type of bone marrow cancer that is resistant to several standard therapies, according to results of a clinical trial published in The New England Journal of Medicine in August.
A next-generation clinical trial program and the first-ever adaptive platform trial for brain cancer, GBM AGILE is a move away from the traditional, one-size-fits-all approach to clinical trials – a major step forward for Precision Medicine.
MD Anderson researchers find tumor microbiome influences immune response and patient survival in pancreatic cancer. Study points to fecal transplant as possible treatment.
In a Phase III clinical trial, the drug volanesorsen significantly reduced blood fat (triglyceride) levels in participants with a rare disease called familial chylomicronemia syndrome; finding could also help inform better prevention methods and treatments for many types of heart disease.
Bolstered by more than $37 million in renewed funding from the National Institutes of Health, four institutions in The University of Texas System, along with Rice University, are partnering to expand clinical and translational research, producing better health outcomes for those in Texas and across the nation.
The George Washington University Cancer Center was selected as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma.
The Executive Committee of the Congress of Neurological Surgeons (CNS) voted unanimously during its winter Executive Committee meeting to approve a $1 million gift to the Congress of Neurological Surgeons Foundation (CNS Foundation). The CNS Foundation’s mission is to improve worldwide patient health by supporting innovative programs that allow neurosurgeons to collaborate globally as researchers, learners, educators and caregivers.
The pivotal trial to determine the safety and effectiveness of a modular device designed to be the first completely off-the-shelf endovascular solution for aortic aneurysms involving the visceral branch vessels is successfully underway with its first surgery at UNC Hospitals in Chapel Hill, NC.
The first surgery in New Jersey using the ROSA Brain robot was performed by Ronald Benitez, MD, chief of endovascular neurosurgery, Overlook Medical Center. Conventional brain surgery for epilepsy requires a craniotomy. Using ROSA Brain, surgeons make tiny holes in the skull through which they insert electrodes to record brain activity and help pinpoint exactly which part of the brain is responsible for seizures. The robot can also assist in deep brain stimulation, trans-nasal and ventricular endoscopy, and brain biopsies.
Clinical trials are a critical tool for getting new treatments to people who need them, but research shows that difficulty finding the right volunteer subjects can undermine the effectiveness of these studies. Researchers designed and tested a new computerized solution that used artificial intelligence (AI) to effectively identify eligible subjects from Electronic Health Records (EHRs), allowing busy clinical staff to focus their limited time on evaluating the highest quality candidates
The NIAID has awarded the University of Alabama at Birmingham Department of Pediatrics a $10. million contract to conduct a multicenter, multinational natural history study of acute flaccid myelitis (AFM) in pediatric patients.
Researchers at the Icahn School of Medicine at Mount Sinai have developed a novel vaccine consisting of DNA and recombinant proteins⸺proteins composed of a portion of an HIV protein and another unrelated protein.
This study, co-led by Samantha Meltzer-Brody, MD, MPH, director of the UNC Perinatal Psychiatry Program, and Daisy Singla, PhD, assistant professor of psychiatry at University of Toronto and clinician scientist at Sinai Health System, will investigate how to make talk therapy treatment – specifically behavioral activation – more accessible to all women.
A highly competitive $4.5 million grant from the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) will support Keck School of Medicine of USC efforts to recruit patients from underrepresented populations into cardiac surgery clinical trials.
SimPHARM is a clinical therapeutic simulation tool that creates a realistic clinical experience in which one minute of virtual time equals one minute of real time. Ideal for flipped classroom learning environments, the platform's cognitive game engine empowers students to develop their clinical decision-making skills at their own pace while under the supervision of faculty. It is built on mathematical models of the physiology of body systems that simulates real life reactions to diseases and drugs. This allows the student to sense and feel the consequences of their decisions.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Bio-Rad’s IH-500, an automated random access system for blood typing and screening.
A drug belonging to a new generation of acute migraine headache treatments was found to eliminate pain and reduce bothersome symptoms for people with migraine in a large-scale trial reported in the July 11 issue of The New England Journal of Medicine. The drug, rimegepant, is awaiting U.S. Food and Drug Administration approval and may offer advantages over currently available migraine medications. The study was led by researchers at Albert Einstein College of Medicine and Montefiore Health System.
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients. Over 850 million people suffer from kidney diseases worldwide, a number which signifies epidemic proportions, yet these patients are still ignored by investigators and initiators of clinical trials in all medical fields – and are thus excluded from clinical trials. ASN, ERA-EDTA and ISN, collaboratively aim to bring about a paradigm change in medical research and have launched an information campaign to that end.